diphtherial

diph·the·ri·al

, diphtheritic (dif-thēr'ē-ăl, dif-thĕ-rit'ik), Relating to diphtheria, or the membranous exudate characteristic of this disease. Synonym(s): diphtheric

diph·the·ri·al

, diphtheritic (dif-thēr'ē-ăl, dif'thĕ-rit'ik) Relating to diphtheria, or the membranous exudate characteristic of this disease.

diphtheria

(dif-ther'e-a) [Gr. diphthera, hide, membrane + -ia] A rare toxin-mediated bacterial infectious disease marked by the formation of a patchy grayish-green membrane over the tonsils, uvula, soft palate, and posterior pharynx. Occasionally the skin, conjunctiva, ears, GI and urinary tracts are involved. In cutaneous diphtheria, impetiginous lesions occur. The membrane is created by a thick, inflammatory exudate. See: antitoxin; exotoxin; sepsis; diphtheria toxoiddiphtherial (-ther'e-al), adjective

Etiology

The causative organism is Corynebacterium diphtheriae. Airborne droplets transmit the organism from person to person (usually from asymptomatic carriers or convalescent patients). More people carry the disease than actually contract an active infection. An effective vaccination program has made the incidence of the disease rare in the US except among groups of people who do not receive immunizations. The lack of virulent strains to reinforce immunity, however, has resulted in loss of immunity in some older adults. The incubation period is 2 to 5 days and occasionally longer.

Immunization

Immunization is by administration of three doses at least 4 weeks apart, beginning at 2 months of age. Diphtheria toxoid (inactivated exotoxin capable of stimulating antibody production) is given in combination with pertussis vaccine (usually acellular pertussis) and tetanus toxoid; a fourth dose is given 1 year later. Booster doses are administered if a child under 6 years old or other close family member is exposed to diphtheria. Because effective immunity does not last longer than 10 years after the last vaccination, people should receive a booster of diphtheria toxoid every 10 years. Immunity to diphtheria is assessed by measuring antibody levels in the blood.

Symptoms

Patients present with fever, malaise, cervical lymphadenopathy, and sore throat, raspy cough, hoarseness, and other croup-like symptoms. A tough yellow-white or gray-green pseudomembrane forms in the throat. It contains cellular debris and fibrin and, unlike the exudate caused by streptococci, is difficult to remove and can obstruct air flow, resulting in stridor, suprasternal retractions, tachypnea, cyanosis, and death by suffocation if not treated. As the bacteria multiply, they produce a potent exotoxin that prevents protein synthesis in cells. Once the exotoxin has spread to the bloodstream, signs of sepsis develop. The toxin can cause peripheral nerve paralysis, thrombocytopenia, renal and pulmonary involvement, and myocarditis, with ventricular fibrillation resulting in death.

Differential Diagnosis

Similar symptoms may be due to tonsillitis, scarlet fever, acute pharyngitis, streptococcal sore throat, peritonsillar abscess, infectious mononucleosis, necrotizing ulcerative gingivitis, acute moniliasis, primary HIV retroviral syndrome, and staphylococcal infections in the respiratory tract after chemotherapy. Examination of a smear from the infected area is advisable; cultures should be obtained in every instance to confirm the diagnosis. In the laryngeal type of diphtheria, edema of the glottis, foreign bodies, and retropharyngeal abscess must be considered.

Treatment

If an adult or unimmunized child shows signs of infection, diphtheria antitoxin, containing preformed antibodies, is administered immediately without waiting for laboratory confirmation. Because antitoxin is made from animal serum, type III hypersensitivity must first be assessed with an intradermal injection of 1:10 dilute antitoxin. If testing is positive, desensitization should be attempted even though it is time-consuming and not without risk. When antitoxin is administered, epinephrine 1:1000 and resuscitation equipment should be on standby, and the patient should be closely observed for anaphylaxis. Intravenous erythromycin administered for 7 to 14 days may decrease exotoxin production by C. diphtheriae and limit spread of the disease although it may sometimes cause thrombophlebitis.

Patient care

The patient is monitored for respiratory distress, sepsis, and myocardial or neural involvement. Humidified oxygen is administered to maintain saturated hemoglobin (SaO₂) above 92%, and the patient is assessed for increased ventilatory effort, use of accessory muscles, nasal flaring, stridor, cyanosis, and agitation or decreased level of consciousness. If airway obstruction occurs, intubation, tracheostomy, mechanical ventilation, or other life-support may be required. Hypotension, tachycardia, and crackles on auscultation may indicate heart failure. Sepsis may produce fever, tachycardia, and hypotension. Neuromuscular involvement is assessed through weakness, paralysis, or sensory changes. All data are clearly documented. Patients who receive antitoxin are closely observed for local or systemic anaphylaxis.

Strict isolation is maintained until two consecutive negative nasopharyngeal cultures have been obtained at least 1 week after drug therapy ceases. Unimmunized members of the patient's household are advised to receive diphtheria toxoid appropriate for age and to complete the proper series of diphtheria immunizations. Even if previously immunized, a person should receive a booster immunization if more than 10 years has passed since the last vaccination. All cases of diphtheria must be reported to local public health authorities. Families are to be prepared for a prolonged convalescence esp. if the patient has neuromuscular involvement.

cutaneous diphtheria

A skin infection, usually at the site of a wound, caused by C. diphtheriae, usually occurring in humid, tropical regions with poor sanitation. It is characterized by slow healing and shallow ulcers containing a tough grayish membrane. It is treated with diphtheria antitoxin and penicillin or erythromycin.

laryngeal diphtheria

A complication of diphtheria caused by extension of the membrane from the pharynx with gradual occlusion of the airway. The signs are restlessness, use of accessory respiration muscles, and development of cyanosis. If this condition is not remedied effectively, death results.

surgical diphtheria

Diphtheritic membrane formation on wounds.

单词	diphtherial
释义	diphtherial diph·the·ri·a D0238200 (dĭf-thîr′ē-ə, dĭp-)n. An acute infectious disease caused by the bacterium Corynebacterium diphtheriae, which infects mucous membranes of the throat, causing formation of a thick layer called the false membrane that can obstruct breathing, and producing a potent toxin that enters the bloodstream and causes systemic effects that include damage to the heart and nervous system. [New Latin diphthēria, from French diphthérie, from Greek diphtherā, piece of hide, leather; see letter.] diph′the·rit′ic (-thə-rĭt′ĭk), diph·ther′ic (-thĕr′ĭk), diph·the′ri·al adj. EncyclopediaSeediphtheria diphtherial diph·the·ri·al , diphtheritic (dif-thēr'ē-ăl, dif-thĕ-rit'ik), Relating to diphtheria, or the membranous exudate characteristic of this disease. Synonym(s): diphtheric diph·the·ri·al , diphtheritic (dif-thēr'ē-ăl, dif'thĕ-rit'ik) Relating to diphtheria, or the membranous exudate characteristic of this disease. diphtheria (dif-ther'e-a) [Gr. diphthera, hide, membrane + -ia] A rare toxin-mediated bacterial infectious disease marked by the formation of a patchy grayish-green membrane over the tonsils, uvula, soft palate, and posterior pharynx. Occasionally the skin, conjunctiva, ears, GI and urinary tracts are involved. In cutaneous diphtheria, impetiginous lesions occur. The membrane is created by a thick, inflammatory exudate. See: antitoxin; exotoxin; sepsis; diphtheria toxoiddiphtherial (-ther'e-al), adjective Etiology The causative organism is Corynebacterium diphtheriae. Airborne droplets transmit the organism from person to person (usually from asymptomatic carriers or convalescent patients). More people carry the disease than actually contract an active infection. An effective vaccination program has made the incidence of the disease rare in the US except among groups of people who do not receive immunizations. The lack of virulent strains to reinforce immunity, however, has resulted in loss of immunity in some older adults. The incubation period is 2 to 5 days and occasionally longer. Immunization Immunization is by administration of three doses at least 4 weeks apart, beginning at 2 months of age. Diphtheria toxoid (inactivated exotoxin capable of stimulating antibody production) is given in combination with pertussis vaccine (usually acellular pertussis) and tetanus toxoid; a fourth dose is given 1 year later. Booster doses are administered if a child under 6 years old or other close family member is exposed to diphtheria. Because effective immunity does not last longer than 10 years after the last vaccination, people should receive a booster of diphtheria toxoid every 10 years. Immunity to diphtheria is assessed by measuring antibody levels in the blood. Symptoms Patients present with fever, malaise, cervical lymphadenopathy, and sore throat, raspy cough, hoarseness, and other croup-like symptoms. A tough yellow-white or gray-green pseudomembrane forms in the throat. It contains cellular debris and fibrin and, unlike the exudate caused by streptococci, is difficult to remove and can obstruct air flow, resulting in stridor, suprasternal retractions, tachypnea, cyanosis, and death by suffocation if not treated. As the bacteria multiply, they produce a potent exotoxin that prevents protein synthesis in cells. Once the exotoxin has spread to the bloodstream, signs of sepsis develop. The toxin can cause peripheral nerve paralysis, thrombocytopenia, renal and pulmonary involvement, and myocarditis, with ventricular fibrillation resulting in death. Differential Diagnosis Similar symptoms may be due to tonsillitis, scarlet fever, acute pharyngitis, streptococcal sore throat, peritonsillar abscess, infectious mononucleosis, necrotizing ulcerative gingivitis, acute moniliasis, primary HIV retroviral syndrome, and staphylococcal infections in the respiratory tract after chemotherapy. Examination of a smear from the infected area is advisable; cultures should be obtained in every instance to confirm the diagnosis. In the laryngeal type of diphtheria, edema of the glottis, foreign bodies, and retropharyngeal abscess must be considered. Treatment If an adult or unimmunized child shows signs of infection, diphtheria antitoxin, containing preformed antibodies, is administered immediately without waiting for laboratory confirmation. Because antitoxin is made from animal serum, type III hypersensitivity must first be assessed with an intradermal injection of 1:10 dilute antitoxin. If testing is positive, desensitization should be attempted even though it is time-consuming and not without risk. When antitoxin is administered, epinephrine 1:1000 and resuscitation equipment should be on standby, and the patient should be closely observed for anaphylaxis. Intravenous erythromycin administered for 7 to 14 days may decrease exotoxin production by C. diphtheriae and limit spread of the disease although it may sometimes cause thrombophlebitis. Patient care The patient is monitored for respiratory distress, sepsis, and myocardial or neural involvement. Humidified oxygen is administered to maintain saturated hemoglobin (SaO₂) above 92%, and the patient is assessed for increased ventilatory effort, use of accessory muscles, nasal flaring, stridor, cyanosis, and agitation or decreased level of consciousness. If airway obstruction occurs, intubation, tracheostomy, mechanical ventilation, or other life-support may be required. Hypotension, tachycardia, and crackles on auscultation may indicate heart failure. Sepsis may produce fever, tachycardia, and hypotension. Neuromuscular involvement is assessed through weakness, paralysis, or sensory changes. All data are clearly documented. Patients who receive antitoxin are closely observed for local or systemic anaphylaxis. Strict isolation is maintained until two consecutive negative nasopharyngeal cultures have been obtained at least 1 week after drug therapy ceases. Unimmunized members of the patient's household are advised to receive diphtheria toxoid appropriate for age and to complete the proper series of diphtheria immunizations. Even if previously immunized, a person should receive a booster immunization if more than 10 years has passed since the last vaccination. All cases of diphtheria must be reported to local public health authorities. Families are to be prepared for a prolonged convalescence esp. if the patient has neuromuscular involvement. cutaneous diphtheria A skin infection, usually at the site of a wound, caused by C. diphtheriae, usually occurring in humid, tropical regions with poor sanitation. It is characterized by slow healing and shallow ulcers containing a tough grayish membrane. It is treated with diphtheria antitoxin and penicillin or erythromycin. laryngeal diphtheria A complication of diphtheria caused by extension of the membrane from the pharynx with gradual occlusion of the airway. The signs are restlessness, use of accessory respiration muscles, and development of cyanosis. If this condition is not remedied effectively, death results. surgical diphtheria Diphtheritic membrane formation on wounds.
随便看	maskun maskwell mask word masl masla maslac maslach maslach burnout inventory masle maslenitsa maslennikov, ivan maslennikov, ivan ivanovich maslesa, veselin masleša, veselin masli masliaev, vadim masliaev, vadim efimovich maslianino maslin masliukov maslov maslov, mikhail maslov, mikhail stepanovich maslov, petr maslov, petr pavlovich